IGM Biosciences Inc at JPMorgan Healthcare Conference Transcript
&-
Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan. And our next presenting company is IGM Biosciences presenting on behalf of the company's CEO, Fred Schwarzer. (Operator Instructions) With that, Fred, thanks for joining us.
Thanks Eric, and thanks very much to JPMorgan for the opportunity to present. We greatly appreciate it. So this is our forward-looking statement disclosure. We will be making some forward-looking statements in this presentation. And you know, there are a whole bunch of risks out there and things don't always work out exactly the way we hope. And so we'd like to direct you to all of the risk factors that are in our filings with the SEC to describe some of those risks.
As a -- big picture overview, we believe that we are the global leaders in the development of IgM antibodies. As far as we know, we represent the only significant commercial effort anywhere in biotech or pharma that's focused on IgM
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |